Investigation into sartan medicines broadens after ‘potent’ contamination

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/FORGEM)
(Image: Getty/FORGEM)

Related tags valsartan Hetero Labs Ema losartan

The European Medicines Agency has unearthed a ‘sartan’ medication, in losartan, that contains low levels of the carcinogenic substance, N-nitrosodiethylamine.

Following the valsartan scandal, regulators have widened their investigations into other ‘sartans’ and found one case where a batch of losartan medication contained a carcinogenic impurity.

N-nitrosodiethylamine (NDEA) is named by the WHO​ as a “potent carcinogen”​ but is a different substance to that found in the valsartan cases that began the entire investigation​, during which numerous cases of N-Nitrosodimethylamine (NDMA) being found in medicine were observed.

The batch of losartan containing impurities, detected by German regulatory authorities, was produced by Indian active pharmaceutical ingredient (API) producer, Hetero Labs.

The company did not respond to a request for comment.

The net widens

As a result of the European Medicines Agency (EMA)’s discovery, the regulator announced that it would be broadening its investigation to include four other sartan medications: candesartan, irbesartan, losartan and olmesartan.

The EMA revealed that it had not concluded exactly why the sartan medications seem to have an issue with impurities but did note that they are produced with a specific ring structure, “which could potentially lead to the formation of impurities such as NDEA​.

Beyond the announcement, the EMA stated: “Further tests are required to determine the extent of the contamination and whether impurities are present in sartan medicines above levels that can be considered acceptable.”

The agency tempered the news by adding that the levels of contamination discovered in the batch of losartan medication was not enough to pose an “immediate risk” ​to patients.

Related news

Show more

Related products

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

A Guide Through the API Drug Development Pipeline

A Guide Through the API Drug Development Pipeline

Content provided by Lonza Small Molecules | 11-Jul-2023 | Insight Guide

With the complexities associated with API and HPAPI drug development, it’s necessary to lean on the experts. With Q&A sections, insights and articles...

Related suppliers

Follow us


View more